BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the Phase 3 study of ULTOMIRIS™ (ravulizumab-cwvz), the company’s long-acting C5 complement inhibitor, met its ...
Never miss a trade again with the fastest news alerts in the world! This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday. Want the ...
Cuireadh roinnt torthaí i bhfolach toisc go bhféadfadh siad a bheith dorochtana duit
Taispeáin torthaí dorochtana
Aiseolas